Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
June 29, 2020Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
-
June 24, 2020Targovax announces presentation of pre-clinical data from Next Generation ONCOS at AACR Virtual Annual Conference
-
June 23, 2020Targovax announces collaboration to evaluate ONCOS-102 in combination with KEYTRUDA® in mesothelioma
-
June 22, 2020Targovax to present at the upcoming 2020 Virtual European Biotech Investor Day 2020
First quarter 2020
Targovax ASA (OSE: TRVX) announced its first quarter 2020 results on Thursday 7 May 2020.